AbbVie

Humira (adalimumab) is a fully human monoclonal antibody from AbbVie that neutralises tumour necrosis factor alpha (TNF-alpha), a key driver of inflammatory disease. It is used across several chronic inflammatory conditions, including rheumatoid arthritis, Crohn disease, ulcerative colitis, plaque psoriasis and uveitis.

Adalimumab is a biologic antibody that targets TNF-alpha, one of the main chemical messengers of inflammation. In conditions like rheumatoid arthritis

Skyrizi (risankizumab) is an interleukin-23 inhibitor from AbbVie for moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ulcerative colitis. It calms the IL-23-driven inflammatory loop behind these conditions.

In plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, the immune system mistakenly keeps tissues inflamed. A signalling p

Rinvoq (upadacitinib) is an oral Janus kinase (JAK) inhibitor from AbbVie for several immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, giant cell arteritis, ulcerative colitis, and Crohn's disease, usually after an inadequate response to prior therapy such as TNF blockers or DMARDs.

Upadacitinib is a tablet taken once daily. It blocks Janus kinase 1 (JAK1), an enzyme that immune cells use to pass inflammatory signals inside the ce

Venclexta (venetoclax) is a BCL-2 inhibitor from AbbVie used in chronic lymphocytic leukemia and small lymphocytic lymphoma, alone or with other antibodies depending on line of therapy, and with a hypomethylating agent in newly diagnosed acute myeloid leukemia when intensive chemotherapy is not suitable.

Venetoclax is a tablet that blocks BCL-2, a protein leukemia cells use to avoid dying. When BCL-2 is blocked, the cancer cells can no longer survive a